icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
eNrNWF1P2zAUfe+viPKehITRlikt2jrYKoHoCtWmvVRuckOduXbwRyn79XOSwsqUCHCxxGPtm3OvfY+PTx2fbFbEWQMXmNGBG/oHrgM0YSmmNwN3dn3m9d2TYSfO0RrthOk4P4pcJyFIiIFbzvoLQFT4Py/Ov4D+Hrg77DgxW+SQyCdxSmLif0NieYGKMsaJ1wynzgrkkqUDt1CyGnViIbmuYnjH+G9RoATiYDuyO5vPP+yOx0EJ9gJUJYCfI3rTCArUCDNRnAOVIyThhvH7lnoPjbCxmIJgiicwQXI54WyNU0gbU2SICDBKkt2lV8DXBGSZpBE8yJOVMAJHOdpM4XbcXPQnPTuSG+kdeGEv7PV7x92o1z8IjVLxna1q7oJeRJDMdaZu1I0CoNWygoKn4Tw67nejqF8NiiBHBDMdyzjUMVkyj/q9o8NeWEagBaMUVrrrHiLAJXiwQpgYtnjCuETEUnOxGD3lp6U8HG6fJVGKRUHQvZ+LwnSrEEd6GrhWEXsLKVdwzbWuEb1n/+FTRUjwyqpnW9WxVHEpaiOmqGwRn7Op6UaMGJWwae+omV7KzZaLGMTbwf5htPmumKgFwYmpMmrtUiDkbDpuF8Z3qCmfkYAZtycqPzBN2Z14e7HaJYel6otKbxtBH9sWHh0Zn8Vfmokt992p4qyAQMsYFvuo05hmbF9d0uRuhnqg9ntjdWXeWKJxWuybZ6h0ms4PbtPagbF3GOuJRtCvp9emLPuugN9fVT8boXE6eOSH2TVg427RnG4t/PUnpBYKK8Ze8WYBWkpZiI9BsETCE0jvkJ/x93rH7LgDe/9MrFiQ2pLVOm2p9EV9Ab+8yaYH9TmDsq/p3n6/NfeNOSRXsEcfak23przj07cX83+O21rZkyfiYy9N5Y6RxIzasltq0Yi43/Wh+0rPuBaHyyzDLa9ErbyMg/qFatiJg/J1atj5C5jtQDQ=
vqFHcDcp6dCGCXKN